ReviewLife (Basel, Switzerland)2026
Identification of Glycoprotein Biomarkers in Breast Cancer by MALDI.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein glycosylation plays a pivotal role in breast cancer biology, influencing cell proliferation, adhesion, migration, and immune evasion. Aberrant N- and O-glycosylation are hallmarks of neoplastic transformation and serve as sensitive indicators of disease progression. This review aims to characterize glycoprotein biomarkers in breast cancer identified using Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry. We examine specific glycosylation alterations-including hypersialylation, fucosylation, and truncated O-glycans-across different molecular subtypes (Luminal A/B, HER2-positive, TNBC) and assess their diagnostic and prognostic potential. Methodologically, the review contrasts MALDI-based profiling and Imaging Mass Spectrometry (MALDI-IMS) with other proteomic techniques, highlighting MALDI's advantages in throughput and spatial resolution alongside its technical limitations. Furthermore, we discuss emerging frontiers in the field, such as the shift from whole-serum analysis to "liquid biopsy" components (e.g., extracellular vesicles). Ultimately, we argue that implementing quantitative glycoproteomics is essential for advancing personalized oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.